Arixtra(fondaparinux)
Arixtra, Fondaparinux (fondaparinux) is an oligosaccharide pharmaceutical. Fondaparinux was first approved as Arixtra on 2001-12-07. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat myocardial infarction, pulmonary embolism, unstable angina, and venous thrombosis. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Arixtra, Fondaparinux (discontinued: Fondaparinux)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| arixtra | New Drug Application | 2024-12-10 |
| fondaparinux sodium | ANDA | 2025-10-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| venous thrombosis | — | D020246 | I82.40 |
| pulmonary embolism | EFO_0003827 | D011655 | I26 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1652 | Injection, fondaparinux sodium, 0.5 mg |
Clinical
Clinical Trials
96 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thromboembolism | D013923 | — | — | 1 | 2 | 15 | 4 | 14 | 35 |
| Thrombosis | D013927 | — | — | 2 | 4 | 9 | 1 | 13 | 28 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 1 | 1 | 10 | 2 | 12 | 25 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 1 | 2 | 3 | 1 | 7 | 13 |
| Embolism | D004617 | — | — | 1 | 2 | 3 | 1 | 6 | 12 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | 1 | 3 | 2 | 7 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 2 | 1 | 1 | 5 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | 1 | 1 | — | 2 | 1 | 5 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | 2 | 1 | 1 | 4 |
| Thrombophlebitis | D013924 | — | — | — | — | 2 | 1 | 1 | 4 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | — | I82.40 | 1 | 4 | 7 | — | 12 | 23 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | — | 4 | 5 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 1 | — | 1 | 3 |
| Infarction | D007238 | EFO_0009463 | — | — | 1 | 1 | — | 1 | 3 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | 3 | — | — | 3 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | 1 | — | — | 2 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | 2 | — | — | 2 |
| Hemostatic disorders | D020141 | — | — | — | — | 2 | — | — | 2 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | — | 1 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | — | — | 3 | 4 |
| Embolism and thrombosis | D016769 | — | — | — | 1 | — | — | 1 | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 2 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | 1 | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | — | — | — | 1 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | — | — | — | 1 |
| Coronary disease | D003327 | — | — | — | 1 | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | — | — | — | 1 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | 1 | 2 |
| Morbid obesity | D009767 | EFO_0001074 | — | 1 | — | — | — | 1 | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 3 | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 2 | 2 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
| St elevation myocardial infarction | D000072657 | — | — | — | — | — | — | 1 | 1 |
| Drug therapy | D004358 | — | — | — | — | — | — | 1 | 1 |
| Percutaneous coronary intervention | D062645 | — | — | — | — | — | — | 1 | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fondaparinux |
| INN | fondaparinux sodium |
| Description | Fondaparinux (trade name Arixtra) is an anticoagulant medication chemically related to low molecular weight heparins. It is marketed by Viatris. A generic version developed by Alchemia is marketed within the US by Dr. Reddy's Laboratories.
|
| Classification | Oligosaccharide |
| Drug class | antihrombotic indirect selective synthetic factor Xa inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 104993-28-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201202 |
| ChEBI ID | 61033 |
| PubChem CID | 636380 |
| DrugBank | DB00569 |
| UNII ID | X0Q6N9USOZ (ChemIDplus, GSRS) |
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Fondaparinux
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,953 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arixtra, Fondaparinux sodium
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,626 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use